Dual Orexin Receptor Antagonists (DORAs) as an Adjunct Treatment for Smoking Cessation
AbstractSmoking is recognized as the most avoidable cause for multiplicity of chronic diseases. However, smoking cessation rates remain low, in part due to the limited target engagement of the currently approved medications for smoking cessation. Sleep is a promising focus for increasing smoking cessation rates because smokers ’ sleep problems are exacerbated during the first week of smoking abstinence and are associated with poor smoking cessation outcomes. Furthermore, the currently approved smoking cessation pharmacological agents varenicline and nicotine replacement treatment exacerbate sleep problems beyond what wo ...
Source: CNS Drugs - April 22, 2022 Category: Neurology Source Type: research
Varenicline (Chantix): The Smoking Cessation Medication Prescribers May Be Avoiding
Issues Ment Health Nurs. 2022 Apr 12:1-6. doi: 10.1080/01612840.2022.2061806. Online ahead of print.NO ABSTRACTPMID:35412411 | DOI:10.1080/01612840.2022.2061806 (Source: Issues in Mental Health Nursing)
Source: Issues in Mental Health Nursing - April 12, 2022 Category: Nursing Authors: Jeremy Mills Source Type: research
